Panel · Template

Benefit-Risk Panel.

LiveBenefit-Risk Panel

Set the benefits of a medicine against its risks in the open: the decision and its therapeutic context, a conclusion with its main uncertainty, an effects table with a comparator, each seat’s reading, and the measures that would manage the risk.

You getA benefit-risk assessment of about four pages (Standard)

DepthsLight (three seats), Standard (four) or Full (five)

Written byAI specialists, each reading the effects from its function

SourcesEvery effect cited, uncertainty stated for each

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

When to use it

You must judge whether the balance of benefit and risk holds for a new indication, a new population, a new signal or a change of status, and you want the effects and the uncertainty laid out first.

Who it is for. Leads who prepare or review a benefit-risk case: regulatory, medical, safety, evidence and quality leads.

Why most benefit-risk write-ups hide the uncertainty

A comparison of public reports from four regulatory agencies found that none applied explicit weighting, none listed all identified benefits and risks with reasons for inclusion or exclusion, none visualized the assessment, and the FDA review and the EMA summary gave no specific comment on uncertainties tied to listed effects. This template closes those gaps: it lists the favorable and unfavorable effects against a comparator, states the uncertainty for each effect, and does not compute a composite score.^{5Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies’ publicly available documents.,1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Page current as of 19 October 2023.}

What you get

The decision and its therapeutic context. The exact decision (product, indication, population, comparator, and whether it is an approval, a label change or a signal), the severity of the condition, and the current options. Benefit is judged against what is already available and not against nothing.^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Page current as of 19 October 2023.,9International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy.}

A conclusion with its main uncertainty. The verdict as analyst judgment: favorable, favorable with conditions, or not favorable, with the one reason that carries it and the main uncertainty.

An effects table. The central exhibit. Favorable and unfavorable effects with size or frequency and source, the comparator and the uncertainty, and the seat that raised each. Benefits and risks are assessed separately and not folded into one statistic.^{4IMI PROTECT. PhRMA Benefit-Risk Action Team (BRAT) framework.,6European Medicines Agency. Benefit-risk methodology project: update on work package 5, effects table pilot phase I. EMA/74168/2014.}

What each seat concludes, and the weighing. Each seat reads the effects from its function and states the criteria it weights as high importance. Importance is qualitative, because AI seats cannot supply elicited patient preferences.^{3Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health, 2023;26(4).}

Uncertainty, risk minimization and what would change the balance. Uncertainty for each effect, the routine and additional measures that would manage the risk with an owner and a way to know they work, and the evidence that would change the balance.^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).,7CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.,8European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators.}

What is in it, by length

Section	Brief	Standard	Comprehensive
Decision and therapeutic contextThe decision, the condition and the current options	●	●	●
Benefit-risk conclusionThe verdict, the reason and the main uncertainty	●	●	●
Effects tableThe favorable and unfavorable effects	●	●	●
What each seat concludesEach seat’s reading and conclusion	●	●	●
Weighing matrix by seat and criterionHow each seat weights each criterion	–	●	●
Uncertainties and sensitivityThe uncertainty for each effect and what would shift it	●	●	●
Risk minimisation and monitoringThe measures, their owners and how they are judged	–	●	●
What would change the balanceThe evidence that would change the conclusion	●	●	●

A Light assessment has three seats and about two pages. Standard has four seats and adds the weighing matrix and the risk minimization table. Full has five seats and adds a rebuttal round.

Choosing a length

Choose Standard for most decisions. Choose Full when the balance is close or the risk is serious, so that the rebuttal is shown.

The standards and practice behind it

The structure and the checks come from published regulatory and good-practice frameworks for benefit-risk assessment. These are the references we drew on and what we took from each. None of their authors has reviewed the template, and the report does not replace a regulator or a benefit-risk committee.

What we took	From	Where it shows
Start from the therapeutic context, the evidence on benefits and risks, the uncertainty that remains, and the options to manage risk	FDA guidance on benefit-risk assessment for new drug and biologic products, as described in FDA’s guidance recap^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Page current as of 19 October 2023.}	The four-part order of the report
Present key benefits and risks in the order: therapeutic context, benefit, risk, benefit-risk assessment	ICH M4E(R2), the Common Technical Document efficacy guideline^{9International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy.}	The decision and context section first
Assess benefits and risks separately, using a value tree and a summary table	The BRAT framework (PhRMA Benefit-Risk Action Team), described by IMI PROTECT^{4IMI PROTECT. PhRMA Benefit-Risk Action Team (BRAT) framework.}	The effects table, with no composite score
Place the effects table at the consequences step of a structured decision process	The EMA Benefit-Risk Methodology Project (PrOACT-URL) and its effects table pilot^{6European Medicines Agency. Benefit-risk methodology project: update on work package 5, effects table pilot phase I. EMA/74168/2014.}	The effects table as the central exhibit
Treat weights as preference judgments and guard against double counting	Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force (2023)^{3Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health, 2023;26(4).}	Qualitative importance only, stated as such
Reassess an established balance when a new safety signal arises	CIOMS Working Group IV: Benefit-Risk Balance for Marketed Drugs (1998)^{7CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.}	The signal use case: the benefit is established and the new risk is the variable
Separate routine from additional risk minimization measures and judge their effectiveness	EMA GVP Module XVI and FDA’s REMS program^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).,8European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators.}	The risk minimization table with an owner and an effectiveness check

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Page current as of 19 October 2023. Read on 9 October 2026. The guidance PDF itself could not be read; its four-part structure is as the recap describes it.
[2] U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Read on 9 October 2026 at its earlier address; components and elements to assure safe use as listed.
[3] Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health, 2023;26(4). Read as ISPOR’s news release on the report and its abstract page; the report body was not read.
[4] IMI PROTECT. PhRMA Benefit-Risk Action Team (BRAT) framework. Read on 9 October 2026: six steps, value tree, summary table.
[5] Strategy for communicating benefit-risk decisions: a comparison of regulatory agencies’ publicly available documents. Read on 9 October 2026: gaps in the public reports of Health Canada, FDA, EMA and TGA.
[6] European Medicines Agency. Benefit-risk methodology project: update on work package 5, effects table pilot phase I. EMA/74168/2014. Known from search results; the report was not read.
[7] CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998. The PDF was unreadable; the method is as described in secondary summaries.
[8] European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators. Routine and additional measures as described in search summaries; not read in full.
[9] International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy. The file could not be opened (access refused); the benefit-risk section order is from secondary commentary.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

Use cases for the Benefit-Risk Panel

7 ready-to-run use cases. Each opens its own page with the question, the specialists, the standards and the references.

NILiveNew Indication Benefit-Risk ReviewDoes the benefit-risk balance of this product in a new indication clear the bar set by current treatments for that condition?Benefit-Risk PanelRegulatory

Open Open →

LELiveLabel Expansion to a New PopulationIf we extend the label to this population, does the balance hold, given what we know and do not know about that group?Benefit-Risk PanelMedical Affairs

Open Open →

ESLiveEmerging Safety Signal ReassessmentA new signal has emerged on a marketed product. Does the balance remain favourable, and what response is proportionate?Benefit-Risk PanelPharmacovigilance

Open Open →

DTLiveDigital Therapeutic Software RiskThe clinical benefit is shown, but the software carries its own risks. Is the net balance acceptable and under what controls?Benefit-Risk PanelInnovation

Open Open →

OSLiveOver-the-Counter Switch ReviewCan consumers self-select, use and self-monitor this product safely enough, and does access benefit outweigh the loss of prescriber oversight?Benefit-Risk PanelBrand & Marketing

Open Open →

CALiveConditional Approval Conversion ReviewThe confirmatory evidence is in. Does it convert the conditional approval to a full one, and has the balance shifted?Benefit-Risk PanelRegulatory

Open Open →

PRLivePost-Marketing Requirement ReviewA post-marketing requirement has delivered its first results. Do they change the balance, and what do they mean for the risk-minimisation measures in place?Benefit-Risk PanelQuality

Open Open →

To edit a saved template, open New → Panel → From template, or the library rail on the service form.

When to use it

You must judge whether the balance of benefit and risk holds for a new indication, a new population, a new signal or a change of status, and you want the effects and the uncertainty laid out first.

Who it is for. Leads who prepare or review a benefit-risk case: regulatory, medical, safety, evidence and quality leads.

Why most benefit-risk write-ups hide the uncertainty

What you get

A conclusion with its main uncertainty. The verdict as analyst judgment: favorable, favorable with conditions, or not favorable, with the one reason that carries it and the main uncertainty.

What is in it, by length

Section	Brief	Standard	Comprehensive
Decision and therapeutic contextThe decision, the condition and the current options	●	●	●
Benefit-risk conclusionThe verdict, the reason and the main uncertainty	●	●	●
Effects tableThe favorable and unfavorable effects	●	●	●
What each seat concludesEach seat’s reading and conclusion	●	●	●
Weighing matrix by seat and criterionHow each seat weights each criterion	–	●	●
Uncertainties and sensitivityThe uncertainty for each effect and what would shift it	●	●	●
Risk minimisation and monitoringThe measures, their owners and how they are judged	–	●	●
What would change the balanceThe evidence that would change the conclusion	●	●	●

A Light assessment has three seats and about two pages. Standard has four seats and adds the weighing matrix and the risk minimization table. Full has five seats and adds a rebuttal round.

The standards and practice behind it

What we took	From	Where it shows
Start from the therapeutic context, the evidence on benefits and risks, the uncertainty that remains, and the options to manage risk	FDA guidance on benefit-risk assessment for new drug and biologic products, as described in FDA’s guidance recap^{1U.S. Food and Drug Administration. Guidance Recap Podcast: Benefit-Risk Assessment for New Drug and Biologic Products. Page current as of 19 October 2023.}	The four-part order of the report
Present key benefits and risks in the order: therapeutic context, benefit, risk, benefit-risk assessment	ICH M4E(R2), the Common Technical Document efficacy guideline^{9International Council for Harmonisation. ICH M4E(R2): The CTD – Efficacy.}	The decision and context section first
Assess benefits and risks separately, using a value tree and a summary table	The BRAT framework (PhRMA Benefit-Risk Action Team), described by IMI PROTECT^{4IMI PROTECT. PhRMA Benefit-Risk Action Team (BRAT) framework.}	The effects table, with no composite score
Place the effects table at the consequences step of a structured decision process	The EMA Benefit-Risk Methodology Project (PrOACT-URL) and its effects table pilot^{6European Medicines Agency. Benefit-risk methodology project: update on work package 5, effects table pilot phase I. EMA/74168/2014.}	The effects table as the central exhibit
Treat weights as preference judgments and guard against double counting	Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force (2023)^{3Quantitative Benefit-Risk Assessment in Medical Product Decision Making: A Good Practices Report of an ISPOR Task Force. Value in Health, 2023;26(4).}	Qualitative importance only, stated as such
Reassess an established balance when a new safety signal arises	CIOMS Working Group IV: Benefit-Risk Balance for Marketed Drugs (1998)^{7CIOMS Working Group IV. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Geneva, 1998.}	The signal use case: the benefit is established and the new risk is the variable
Separate routine from additional risk minimization measures and judge their effectiveness	EMA GVP Module XVI and FDA’s REMS program^{2U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS).,8European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators.}	The risk minimization table with an owner and an effectiveness check